Rashmi D'mello, MD
Allergy & Immunology · Saint Joseph, MINPI 1558758052
Payments from drug & device makers
Across 48 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$424
- AstraZeneca$360
- Novartis$154
- Regeneron Healthcare Solutions, Inc.$139
- Teva Pharmaceuticals USA, Inc.$120
- CSL Behring$74
- plus $219 from 7 others
What the payments were for
- Food & beverage$1,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 13 | $424 |
| AstraZeneca | 9 | $360 |
| Novartis | 8 | $154 |
| Regeneron Healthcare Solutions, Inc. | 2 | $139 |
| Teva Pharmaceuticals USA, Inc. | 1 | $120 |
| CSL Behring | 4 | $74 |
| Genentech USA, Inc. | 3 | $52 |
| Biocryst Pharmaceuticals, Inc. | 2 | $52 |
| Amgen | 2 | $36 |
| Pharming Healthcare, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,490 in reported general payments places this provider in the 40th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $38,537 |
| Epinephrine | 14 | $3,549 |
| Ipratropium Bromide | 71 | $2,172 |
| Mometasone Furoate | 20 | $2,133 |
| Fluticasone Propionate | 110 | $1,830 |
| Montelukast Sodium | 175 | $1,552 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $635 |
| Levocetirizine Dihydrochloride | 43 | $628 |
| Azelastine Hcl | 14 | $405 |
| Famotidine | 59 | $396 |
| Hydroxyzine Hcl | 18 | $100 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Saint Joseph
- Jeffrey LefleinYpsilanti$7.9M
- Cem AkinNorthville$3M
- Alan BaptistAnn Arbor$2.5M
- Suresh AnneFlint$1.1M
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Rajan RavikumarBrighton$661K
- Georgiana SandersAnn Arbor$607K
- Nicholas HartogGrand Rapids$581K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.